218.2 ð åèç
218.2.0.1 å¿ è â CD4 Threshold for OIs
- PJP < 200
- Toxo, Crypto, MAC, PML, KS < 100
- CMV retinitis < 50
218.2.0.2 å¿ è â Prophylaxis
| CD4 | Drug |
|---|---|
| < 200 + Toxo IgG+ | TMP-SMX (covers PJP + Toxo) |
| < 100 + Toxo IgG+ | TMP-SMX |
| < 100 CrAg+ | Fluconazole (pre-emptive) |
218.2.0.3 å¿ è â PJP
- CD4 < 200, dry cough, hypoxia, bilateral CXR interstitial
- TMP-SMX 15-20 mg/kg/d à 21 days
- Steroid if A-a > 35 or PaO2 < 70
- β-D-glucan elevated; BAL gold standard
218.2.0.4 å¿ è â Toxoplasma
- CD4 < 100 + IgG+
- MRI multi-ring enhancing
- Sulfadiazine + pyrimethamine + leucovorin à 6 wk
- TMP-SMX alt
218.2.0.5 å¿ è â Cryptococcus
- CD4 < 100
- Headache + fever + altered mental status
- Serum CrAg + CSF CrAg + India ink
- Repeated LPs for high pressure (mortality reduction)
- AmB liposomal + flucytosine à 14d â fluconazole 800 à 8 wk â 200 maintenance
- Delay ART 4-6 wk after cryptococcal meningitis treatment (COAT trial)
218.2.0.6 å¿ è â MAC
- CD4 < 50
- Fever + weight loss + anemia + LAP + splenomegaly
- Blood culture (mycobacterial bottles)
- Clarithromycin + ethambutol + rifabutin ⥠12 mo + immune recovery
218.2.0.7 å¿ è â CMV Retinitis
- CD4 < 50
- âPizza pieâ fundus
- Valganciclovir 900 PO bid à 21 d induction â 900 qd maintenance
218.2.0.8 å¿ è â Toxo vs PCNSL
- Toxo: multi-ring enhancing, response to empirical therapy
- PCNSL: single homogeneous enhancing, EBV PCR+, thallium SPECT+